Elucidation of DNA Primase as a Drug Target in Leishmania donovani: Structure-Guided Inhibitor Identification and Biochemical Validation
Abstract
Replication is started by DNA primase, which synthesizes an oligoribonucleotide primer that DNA polymerases extend. Effective chemotherapy is still needed to manage and treat leishmaniasis, which continues to pose a threat to public health around the world. Repurposing drugs offers alternative uses for drugs with established pharmacological effects, saving money and increasing the pool of human resources available to create novel anti-leishmanials. Here, we used a non-radioactive primase-pyrophosphatase assay to biochemically characterize the Leishmania donovani nuclear DNA primase (LdPri) subunits, followed by in silico evaluation of inhibitors targeting LdPri. The best-evaluated inhibitors showed LdPri inhibition in vitro under conditions similar to those of the primase-pyrophosphatase experiment. The MTT assay also confirmed the inhibitors' anti-leishmanial properties. Parasite growth and morphological analysis were performed by culturing cells in the presence of inhibitors. Biochemical characterization revealed that LdPriS activity was unstable, but was highly stabilized upon association with LdPriL in LdPri. LdPri was found to be thermostable and possesses 3'-terminal nucleotidyltransferase activity. Additionally, in silico and in vitro studies evaluated Pritelivir (BAY 57-1293) as the most efficient LdPri complex inhibitor, followed by Epigallocatechin Gallate (EGCG). Moreover, kinetic studies showed that Pritelivir and EGCG exhibit competitive and uncompetitive…
Read the paper
Related studies
- eggNOG 5.0: a hierarchical, functionally and phylogenetically annotated orthology resource based on 5090 organisms and 2502 viruses
- Online Survival Analysis Software to Assess the Prognostic Value of Biomarkers Using Transcriptomic Data in Non-Small-Cell Lung Cancer
- OptiType: precision HLA typing from next-generation sequencing data
- Nicotinic Cholinergic System and COVID-19: In Silico Identification of an Interaction between SARS-CoV-2 and Nicotinic Receptors with Potential Therapeutic Targeting Implications
- Saccharomyces cerevisiae cells have three Omega class glutathione S-transferases acting as 1-Cys thiol transferases
- Hemolysis at low blood flow rates: in-vitro and in-silico evaluation of a centrifugal blood pump
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.